Peter Harwin
Co-Founder and Managing Member @ Fairmount Funds Management
Greater Philadelphia Area, United States
Peter Harwin is a post-ipo equity investor at Fairmount Funds Management in Greater Philadelphia Area focused on Health Care and Biotechnology. Peter Harwin is the Co-Founder and Managing Member of Fairmount Funds Management. He attended Emory University in 2004.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Peter Harwin invests in
Stages Peter Harwin invests in
Countries Peter Harwin invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Biotechnology 2 (67%)
- Medical 1 (33%)
- Therapeutics 1 (33%)
- Health Diagnostics 1 (33%)
Country
- Denmark 1 (33%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Galecto
|
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $284.9M / Post-IPO Equity / Nov 10, 2025 | |
Cogent Biosciences
|
Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety andefficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, Massachusetts. | $225M / Post-IPO Equity / Feb 13, 2024 | |
|
Cogent Biosciences
|
Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety andefficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, Massachusetts. | $104.4M / Post-IPO Equity / Jul 06, 2020 |
Co-Investors
Fairmount Funds Management is a Philadelphia-based investment firm.
Fairmount Funds Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Peter Harwin
Co-Founder and Managing Member
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Peter Harwin invest in?
Peter Harwin invests primarily in Health Care, Biotechnology and Medical startups, most often at Post-IPO Equity stage. Most of the 3 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Peter Harwin?
Public channels for Peter Harwin include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Peter Harwin last invest?
The most recent investment recorded for Peter Harwin closed in Nov 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
